Azitra, Inc. AZTR
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
Azitra, Inc. (AZTR) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -167%.
About Azitra
Azitra is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. It was profitable in 0 of the last 4 years in our data. Its share count rose by 13810% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $7500 | $686000 | $284000 |
| Net income | -$11M | -$9M | -$11M | -$11M |
| Free cash flow | -$11M | -$10M | -$7M | -$8M |
| EPS (diluted) | $-2.25 | $-15.70 | $-54.98 | $-383.78 |
| Net margin | — | -119600.0% | -1644.9% | -3760.7% |
| ROIC | -205.6% | -139.3% | -156.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $3.50, 475% above the current price; targets range from $3.00 to $4.00; the consensus rating is “Buy”; expected EPS is $-2.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Azitra pay a dividend?
Not currently.
Is Azitra a good stock to buy?
We do not give buy or sell advice. Azitra scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.